Baseline Demographic, Medical Characteristics, and Quality-of-Life Scores of All HSNI Users and Current Study Participants
| Characteristic | Phase 1 and 2 HSNI Users (n = 66) | Current Study/Phase 3 Participants (n = 28) |
|---|---|---|
| HSNI = hypertonic saline nasal irrigation; RSDI = Rhino Sinusitis Disability Index; SIA = single-item assessment. | ||
| * Using a 30-item validated multidimensional disease-specific assessment instrument, participants scored their sinus symptoms: 0 = maximal impact of sinus symptoms on quality of life, 100 = no impact. | ||
| † Using a 1-7 Likert scale, where 1 = no impact, and 7 = maximal impact, participants responded to the statement: “Please evaluate the overall severity of your sinus symptoms since enrolled in the study.” | ||
| Age, y ± SEM | 42.4 ± 1.3 | 44.8 ± 1.8 |
| Female, No. (%) | 48 (73 ) | 19 (68 ) |
| Baseline RSDI,* No. ± SEM | 58.8 ± 1.8 | 57.2 ± 2.9 |
| Baseline SIA,† No. ± SEM | 3.95 ± 0.12 | 4.02 ± 0.20 |
| Seasonal allergies, No. (%) | 44 (67 ) | 21 (75 ) |
| Asthma, No. (%) | 16 (24 ) | 7 (25 ) |
| Nasal surgery, No. (%) | 25 (38 ) | 12 (43 ) |
| Nasal polyps, No. (%) | 11 (17 ) | 3 (11 ) |
| Deviated septum, No. (%) | 16 (24 ) | 8 (29 ) |
| Quality-of-life scores at end of phase 2 | ||
| End of phase 2 RSDI, No. ± SEM | 77.9 ± 1.8 | 80.1 ± 2.9 |
| End of phase 2 SIA, No. ± SEM | 2.36 ± 0.13 | 2.29 ± 0.18 |